Use of RUNX3 and miR-532-5p as cancer markers and therapeutic targets

Details for Australian Patent Application No. 2009260022 (hide)

Owner John Wayne Cancer Institute

Inventors Kitago, Minoru; Hoon, Dave S. B.

Agent Spruson & Ferguson

Pub. Number AU-A-2009260022

PCT Pub. Number WO2009/155455

Priority 61/074,108 19.06.08 US

Filing date 18 June 2009

Wipo publication date 23 December 2009

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

G01N 33/53 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Immunoassay

Event Publications

23 December 2010 PCT application entered the National Phase

  PCT publication WO2009/155455 Priority application(s): WO2009/155455

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009260024-Improved peptide mediators of cholesterol efflux

2009260005-Mechanism for 3rd generation partnership project multiple inter-network quality of service continuity